Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As ...

Discover how simple lifestyle changes — like exercise, diet, and better sleep — can help reduce symptoms and improve quality ...

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

This variability contributes to delayed diagnosis, with many people enduring symptoms for years before receiving proper treatment. Left untreated, psoriatic arthritis can lead to permanent joint ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

In February 2025, A naptysBio announced promising results from a global Phase IIb trial (RENOIR) for rosnilimab, a novel ...

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.

The National Psoriasis Foundation will host its annual Commit to Cure gala on June 18, the organization’s largest fundraiser ...